


Delapril

Cat. No.:	HY-121232
CAS No.:	83435-66-9
Molecular Formula:	C ₂₆ H ₃₂ N ₂ O ₅
Molecular Weight:	452.54
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Delapril (CV-3317) is an orally active angiotensin I converting enzyme (ACE) inhibitor. Delapril has antihypertensive activity ^[1] .								
In Vivo	<p>Delapril (5-20 mg/kg, fed in drinking water) slows the progression of atherosclerosis in cholesterol-fed rabbits^[2]. Delapril (1-10 mg/kg, p.o., daily for 5 weeks) shows antihypertensive effect spontaneously in hypertensive rats^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cholesterol-fed rabbits^[2]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg at D5, 10 mg/kg at D10, 20 mg/kg at D20</td> </tr> <tr> <td>Administration:</td> <td>Fed in a fixed volume (10 ml) of drinking water</td> </tr> <tr> <td>Result:</td> <td>Decreased aortic area covered by lesions. Restored endothelium-dependent relaxation</td> </tr> </table>	Animal Model:	Cholesterol-fed rabbits ^[2]	Dosage:	5 mg/kg at D5, 10 mg/kg at D10, 20 mg/kg at D20	Administration:	Fed in a fixed volume (10 ml) of drinking water	Result:	Decreased aortic area covered by lesions. Restored endothelium-dependent relaxation
Animal Model:	Cholesterol-fed rabbits ^[2]								
Dosage:	5 mg/kg at D5, 10 mg/kg at D10, 20 mg/kg at D20								
Administration:	Fed in a fixed volume (10 ml) of drinking water								
Result:	Decreased aortic area covered by lesions. Restored endothelium-dependent relaxation								

REFERENCES

- [1]. Onoyama K, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. *Clin Pharmacol Ther.* 1988 Mar;43(3):242-9.
- [2]. Hernandez A, et al. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. *Atherosclerosis.* 1998 Mar;137(1):71-6.
- [3]. Inada Y, et al. Antihypertensive action of a non-sulphydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models. *Jpn J Pharmacol.* 1986 Sep;42(1):1-8.
- [4]. Onoyama K, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. *Clin Pharmacol Ther.* 1988 Mar;43(3):242-9.
- [5]. Hernandez A, et al. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. *Atherosclerosis.* 1998 Mar;137(1):71-6.
- [6]. Inada Y, et al. Antihypertensive action of a non-sulphydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models. *Jpn J Pharmacol.* 1986 Sep;42(1):1-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA